Updated Monday, 10/4.
In the first full week of October, seven IPOs are slated to raise $2.0 billion, led by two fitness companies.
Fitness chain Life Time Group Holdings (LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 "centers" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.
Fitness equipment brand iFIT Health & Fitness (IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.
Proteomics platform IsoPlexis (ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.
Biotech Theseus Pharmaceuticals (THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.
Tumor biotech Pyxis Oncology (PYXS) plans to raise $125 million at a $493 million market cap. The company is developing its ADC candidates and mAb preclinical discovery programs for difficult-to-treat solid and hematologic tumors. Pyxis anticipates submitting INDs for two of its ADC candidates by mid-2022, and another candidate by 2023.
Drug developer Cingulate (CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.
Alzheimer's biotech Cognition Therapeutics (CGTX) plans to raise $40 million at a $299 million market cap. Cognition's lead program, CT1812, is a small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. CT1812 is currently in enrolling patients in a Phase 2 trial in patients with mild-to-moderate Alzheimer's disease.
| U.S. IPO Calendar | |||
|---|---|---|---|
| Issuer Business | Deal Size Market Cap | Price Range Shares Filed | Top Bookrunners |
| iFIT Health & Fitness (IFIT) Logan, UT | $600M $6,446M | $18 - $21 30,769,231 | Morgan Stanley BofA |
| Sells connected home fitness equipment and monthly class subscriptions. | |||
| Cingulate (CING) Kansas City, KS | $50M $225M | $10 - $12 4,545,454 | Oppenheimer Ladenburg |
| Phase 3-ready biotech developing formulations of stimulant drugs for ADHD. | |||
| Life Time (LTH) Chanhassen, MN | $901M $4,055M | $18 - $21 46,200,000 | Goldman Morgan Stanley |
| Premium US health and fitness chain. | |||
| Theseus Pharma (THRX) Cambridge, MA | $125M $593M | $14 - $16 8,333,500 | Jefferies SVB Leerink |
| Preclinical biotech developing pan-variant kinase inhibitors for solid tumors. | |||
| Cognition Therapeutics (CGTX) Purchase, NY | $40M $299M | $11 - $13 3,350,000 | B. Riley Oppenheimer |
| Phase 2 biotech developing small molecule therapies for Alzheimer's and other CNS diseases. | |||
| IsoPlexis (ISO) Branford, CT | $125M $648M | $14 - $16 8,333,000 | Morgan Stanley Cowen |
| Provides a single-cell proteomics platform for drug development. | |||
| Pyxis Oncology (PYXS) Cambridge, MA | $125M $493M | $14 - $16 8,340,000 | BofA Jefferies |
| Preclinical biotech developing antibody therapies for solid and hematologic tumors. | |||
Sign up for a free trial of our premium platform, IPO Pro. Follow us on Twitter (@IPOtweet) and register for our updates on the IPO market.
Lock-up periods will be expiring for up to two companies in the week ahead. For access to Street research and lock-up expiration dates, sign up for a free trial of IPO Pro.
IPO Market Snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 9/30/2021, the Renaissance IPO Index was up 0.2% year-to-date, while the S&P 500 was up 14.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Moderna (MRNA) and Uber Technologies (UBER). The Renaissance International IPO Index was down 17.8% year-to-date, while the ACWX was up 5.6%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Meituan-Dianping and SoftBank.
